ACUTE MYELOID LEUKEMIA

This early-phase study tested a new type of stem cell transplant (microtransplantation) in 25 people with acute myeloid leukemia or myelodysplastic syndromes who were too old or sick for a standard transplant. Unlike standard transplants, this approach used partially matched fami…

This study tested a combination of two drugs, azacitidine and venetoclax, as an initial treatment for adults aged 60 and older with acute myeloid leukemia (AML) who had not received prior therapy. Participants received the drugs together as induction therapy, and those who respon…

This early-phase study tested a combination of two drugs, pevonedistat and decitabine, in 12 people with high-risk acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants had AML that was…

This study tested a drug called guadecitabine combined with donor white blood cell infusions in 55 adults whose leukemia or MDS came back after a stem cell transplant. The goal was to see if the drug could help the donor cells fight the cancer more effectively. The treatment aims…

This early-phase trial tested a mix of a cancer vaccine, chemotherapy, and immunotherapy in 8 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with low blast counts. The goal was to see if the combination is safe and helps the immune system fight cancer …

This early-phase study tested the drug regorafenib in 16 adults with advanced blood cancers like acute myeloid leukemia (AML) that had stopped responding to other treatments. The main goal was to find the safest dose and see how the drug affects cancer-related cell signals. While…

This study tested a new treatment for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers took immune cells (NK cells) from the original donor, trained them to become 'memory-like' using cytokines, and gave them back to patie…

This early-phase study tested two drugs, bortezomib and lenalidomide, in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a stem cell transplant. The main goal was to find the safest dose and see if the combination could reduce cancer…

This early-stage study tested a new drug called JNJ-74856665 in 153 people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal was to find safe doses and check for side effects. The drug works by blocking a key enzyme cancer cells need to grow. Thi…

This study tested whether adding the drug quizartinib to standard chemotherapy helps adults with a common type of acute myeloid leukemia (AML) that lacks a specific FLT3 mutation. About 273 newly diagnosed patients aged 18 to 70 took part. The main goal was to see if the combinat…

This early-phase study tested whether adding two targeted drugs (gemtuzumab ozogamicin and midostaurin) to standard chemotherapy is safe for people with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). The study involved 21 newly diagnosed patients and aimed …

This study tested whether a new combination of drugs (venetoclax plus CACAG) works better than the standard treatment for people newly diagnosed with acute myeloid leukemia (AML). About 200 patients aged 14 to 75 took part. The goal was to see if more patients achieved remission …

This study tested a personalized geriatric optimization plan (GO!) in 30 patients over 60 receiving a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see if these changes …

This study looked at how well the drug venetoclax works for adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. About 120 people in Switzerland and Austria took venetoclax pills daily as part of their normal care. Researche…

This early-phase study tested a combination of two drugs—veliparib and temozolomide—in 66 adults with acute leukemias that had come back or not responded to standard treatment. The goal was to find the safest dose and see how well the combo worked. Veliparib blocks a repair enzym…

This early-phase study tested adding the cholesterol drug pitavastatin to the standard cancer drug venetoclax for people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Only 6 people took p…

This early-phase trial tested a drug called ONC-201 in 20 people with acute myeloid leukemia or myelodysplastic syndrome who had recently received a stem cell transplant. The goal was to see if taking ONC-201 weekly for a year could help prevent the cancer from coming back. The s…

This phase 2 trial tested whether adding ready-made donor natural killer (NK) cells to a standard stem cell transplant could safely reduce the chance of cancer coming back in people with high-risk myeloid cancers like AML, MDS, and CML. Twenty-four patients received the combinati…

This study tested whether a combination of two chemotherapy drugs (clofarabine and intermediate-dose cytarabine, called CLARA) works better than high-dose cytarabine alone (HDAC) to keep acute myeloid leukemia (AML) from coming back after initial treatment. It included 735 younge…

This study tested a new drug called gilteritinib alongside standard chemotherapy in 97 adults newly diagnosed with acute myeloid leukemia (AML), including those with a specific genetic change (FLT3 mutation). The first part aimed to find the safest dose, and the second part measu…

This study tested a less intense stem cell transplant for people with various blood cancers who are older or have other health issues. It used a half-matched family donor (like a parent or sibling) and a milder chemo and radiation preparation. The goal was to see how many patient…

This study tested a new drug called siremadlin added to two standard medicines (venetoclax and azacitidine) in adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The goal was to see if the combination could improve response in patients wh…

This study tested a new drug called S65487 combined with azacitidine in 57 adults with untreated acute myeloid leukemia who were not healthy enough for intensive treatment. The goal was to see if the combination is safe and can help achieve complete remission. The trial has compl…

This early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The treatment uses specially grown natural killer cells to attack cancer cells. The main goals were to check safety an…

This early-phase study tested an oral drug called NTX-301 in 22 adults with blood cancers (MDS, AML, or CMML) that had not responded to prior treatment. The main goal was to check safety and find the right dose. Researchers also looked for signs that the drug could control the di…

This study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…

This study tested the drug enasidenib as a maintenance therapy after stem cell transplant in 23 people with IDH2-mutant acute myeloid leukemia or chronic myelomonocytic leukemia. The goal was to find the safest dose and see if it could help prevent the cancer from coming back. Pa…

This study tested a new treatment called CTX131 for adults with certain blood cancers (T cell lymphoma, B cell lymphoma, or acute myeloid leukemia) that came back or didn't respond to standard therapy. CTX131 uses CRISPR gene editing to create donor immune cells that target and a…

This early-phase study tested an oral drug called KPT-9274 in 16 adults with acute myeloid leukemia that had come back or not responded to prior treatments. The main goal was to find the safest dose and see how well patients tolerated the drug. The study is complete, but results …

This study tested a new chemotherapy drug called CPX-351 in 56 adults with a fast-growing blood cancer (acute myeloid leukemia) that is hard to treat. The drug combines two standard chemo medicines inside a tiny fat bubble to help them work better together. The goal was to see ho…

This study looked at whether giving the antibiotic levofloxacin can prevent serious infections in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are being treated with azacitidine. Infections are a major risk for these patients. The study enrolled…

This study tested the drug dasatinib in 68 adults with several blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control these diseases and to check its safety. Results focused on how many pa…

This study tested a new way to help people with blood cancers like leukemia and lymphoma get hospice care earlier. Normally, patients delay hospice because they need blood transfusions for symptom relief, but hospices can't afford to provide them. The study paid for transfusions …

This early-phase study looked at how well a combination of two chemotherapy drugs (cytarabine and daunorubicin) works for adults newly diagnosed with acute myeloid leukemia, and whether giving one drug as a continuous infusion might be safer for the heart. About 40 participants r…

This study looked at whether music therapy can ease fatigue and improve certain blood test results in people with acute myeloid leukemia who are receiving chemotherapy for the first time. Sixty adults took part, and researchers measured their fatigue levels and lab values like wh…

This study looked at whether adding a palliative care team (focused on symptom relief and emotional support) to usual cancer care improves quality of life for people with acute myeloid leukemia (AML). Researchers compared two groups of 160 hospitalized adults with high-risk AML. …

This study looked at the tiny organisms (fungi and bacteria) living in the mouth and nose of 62 children with blood cancers or those getting a bone marrow transplant. Researchers wanted to see how these germ communities change after chemotherapy or transplant. The goal was to lea…

This study looked at over 1,700 people with blood cancers or disorders who needed a bone marrow transplant. Researchers compared two strategies: first searching for a matched unrelated donor and then an alternative if needed, versus going straight to an alternative donor. The goa…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and their doctors communicate better and make decisions together. 161 people took part. The goal was to see if the tool improves shared decision-making, not to trea…

This early-phase trial tested whether adding the pneumonia drug atovaquone to standard chemotherapy is feasible for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study enrolled 26 participants and focused on measuring drug levels in the blood an…

This study aims to confirm that measuring two substances in the blood (FLT3L and IL-6) during the first round of chemotherapy can help predict how well patients with acute myeloid leukemia (AML) will do. Researchers will track 201 newly diagnosed AML patients across 25 French hos…

This study looked at frozen ovarian tissue from 9 young women with acute myeloid leukemia (AML) to see if any leukemia cells remained after they reached remission. The goal was to understand the risk of re-introducing cancer if the tissue is later used for fertility. No treatment…

This pilot study looked at 20 adults with acute myeloid leukemia (AML) who cannot have strong chemotherapy. Researchers measured the amount of the drug venetoclax in the blood to see if it relates to how well the drug works and its side effects. The goal is to learn if personaliz…

This study tested a tool called UR-GOAL to help older patients with acute myeloid leukemia (AML), their caregivers, and doctors communicate better about treatment choices. Fifteen patients aged 60 and older, along with their caregivers, used the tool and then gave feedback. The g…

This study tested whether a telehealth program could help older adults (60+) with acute myeloid leukemia or myelodysplastic syndrome plan their future medical care. Researchers worked with 36 patients, their caregivers, and doctors to see if the program was easy to use and practi…

This study looked at people with a specific genetic form of acute myeloid leukemia (FLT3-mutated) whose cancer returned or didn't respond to treatment. Researchers compared those who took the drug gilteritinib after a stem cell transplant to those who received standard care, usin…